Table 3 Risk factors associated with post-operative FSGS recurrence*

Age (per 10-year increase)

0.63 (0.43–0.91)

0.014

0.61 (0.42–0.90)

0.012

Female sex

0.76 (0.24–1.78)

0.40

 N/A

N/A

Dialysis duration (per year)

1.10 (0.98–1.22)

0.10

 N/A

N/A

FSGS to renal failure (per year)

0.98 (0.57–1.07)

0.57

 N/A

N/A

Deceased (vs. living donor)

4.78 (1.73–13.24)

0.003

 N/A

N/A

Pre-transplant treatment

(vs. no treatment)

0.20 (0.07–0.59)

0.004

0.17 (0.05–0.54)

0.003

No pre-transplant treatment

Reference

N/A

N/A

Plasmapharesis only

0.08 (0.01–0.66)

0.019

Plasmaphereses + rituximab

0.30 (0.09–1.01)

0.05

Tacrolimus (vs. cyclosporin)

0.69 (0.22–2.17)

0.53

 N/A

N/A

HLA-A, B, DR mismatch

1.13 (0.84–1.52)

0.42

 N/A

N/A

PRA class I

1.01 (0.99–1.02)

0.66

 N/A

N/A

PRA class II

1.00 (0.98–1.02)

0.92

 N/A

N/A

ABO incompatibility

0.27 (0.06–1.25)

0.09

 N/A

N/A